ADMA Biologics, Inc. (NASDAQ:ADMA) Shares Sold by American Century Companies Inc.

American Century Companies Inc. cut its holdings in shares of ADMA Biologics, Inc. (NASDAQ:ADMA) by 10.4% in the 4th quarter, Holdings Channel reports. The firm owned 3,773,562 shares of the biotechnology company’s stock after selling 436,091 shares during the period. American Century Companies Inc.’s holdings in ADMA Biologics were worth $64,717,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the business. Commonwealth of Pennsylvania Public School Empls Retrmt SYS increased its holdings in shares of ADMA Biologics by 1.3% in the fourth quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 50,466 shares of the biotechnology company’s stock valued at $865,000 after buying an additional 645 shares in the last quarter. Oregon Public Employees Retirement Fund raised its position in shares of ADMA Biologics by 1.3% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 55,600 shares of the biotechnology company’s stock worth $954,000 after purchasing an additional 700 shares during the period. Mutual of America Capital Management LLC lifted its holdings in shares of ADMA Biologics by 2.1% during the fourth quarter. Mutual of America Capital Management LLC now owns 35,807 shares of the biotechnology company’s stock valued at $614,000 after purchasing an additional 751 shares during the last quarter. Maryland State Retirement & Pension System boosted its position in shares of ADMA Biologics by 1.1% in the 4th quarter. Maryland State Retirement & Pension System now owns 79,607 shares of the biotechnology company’s stock valued at $1,365,000 after purchasing an additional 897 shares during the period. Finally, GAMMA Investing LLC increased its stake in ADMA Biologics by 106.6% in the 4th quarter. GAMMA Investing LLC now owns 1,874 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 967 shares in the last quarter. 75.68% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Separately, Cantor Fitzgerald reiterated an “overweight” rating and issued a $25.00 target price on shares of ADMA Biologics in a report on Tuesday, March 4th.

ADMA Biologics Stock Performance

Shares of ADMA stock opened at $20.22 on Wednesday. The company has a market capitalization of $4.78 billion, a price-to-earnings ratio of 72.21 and a beta of 0.60. ADMA Biologics, Inc. has a 1-year low of $5.90 and a 1-year high of $23.64. The company has a current ratio of 7.09, a quick ratio of 3.26 and a debt-to-equity ratio of 0.48. The stock’s fifty day simple moving average is $16.91 and its 200-day simple moving average is $18.10.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.